- Home
- JEF vs IONS Comparison
JEF vs IONS Comparison
Compare JEF & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JEF | IONS |
|---|---|---|
| Founded | 1968 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2B | 12.1B |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | JEF | IONS |
|---|---|---|
| Price | $47.64 | $44.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 22 |
| Target Price | $61.40 | ★ $93.36 |
| AVG Volume (30 Days) | 1.8M | ★ 3.6M |
| Earning Date | 03-25-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $10,823,677,000.00 | N/A |
| Revenue This Year | $13.23 | N/A |
| Revenue Next Year | $10.25 | $77.99 |
| P/E Ratio | $66.06 | ★ N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $35.53 | $43.01 |
| 52 Week High | $69.93 | $86.74 |
Technical Indicators
Market Signals| Indicator | JEF | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 36.92 | 31.17 |
| Support Level | $45.78 | N/A |
| Resistance Level | $49.52 | $78.11 |
| Average True Range (ATR) | 1.80 | 2.46 |
| MACD | -0.36 | -0.73 |
| Stochastic Oscillator | 23.84 | 13.48 |
Price Performance
Historical ComparisonAbout JEF Jefferies Financial Group Inc.
Jefferies Financial Group is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since the merger, Jefferies became the core of the combined business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).